The use of live attenuated influenza vaccine ts-1(E) in man.
Identifieur interne : 002B01 ( Main/Exploration ); précédent : 002B00; suivant : 002B02The use of live attenuated influenza vaccine ts-1(E) in man.
Auteurs : J M GwaltneySource :
- Developments in biological standardization [ 0301-5149 ] ; 1976.
Descripteurs français
- KwdFr :
- Administration par voie nasale, Adulte, Anticorps antiviraux (analyse), Enfant, Essais cliniques comme sujet, Femelle, Grippe humaine (), Humains, Mâle, Sialidase (immunologie), Tests d'inhibition de l'hémagglutination, Vaccins antigrippaux (administration et posologie), Vaccins antigrippaux (effets indésirables), Vaccins antigrippaux (usage thérapeutique), Vaccins atténués (administration et posologie), Vaccins atténués (effets indésirables), Virus de la grippe A (immunologie).
- MESH :
- administration et posologie : Vaccins antigrippaux, Vaccins atténués.
- analyse : Anticorps antiviraux.
- effets indésirables : Vaccins antigrippaux, Vaccins atténués.
- immunologie : Sialidase, Virus de la grippe A.
- usage thérapeutique : Vaccins antigrippaux.
- Administration par voie nasale, Adulte, Enfant, Essais cliniques comme sujet, Femelle, Grippe humaine, Humains, Mâle, Tests d'inhibition de l'hémagglutination.
English descriptors
- KwdEn :
- Administration, Intranasal, Adult, Antibodies, Viral (analysis), Child, Clinical Trials as Topic, Female, Hemagglutination Inhibition Tests, Humans, Influenza A virus (immunology), Influenza Vaccines (administration & dosage), Influenza Vaccines (adverse effects), Influenza Vaccines (therapeutic use), Influenza, Human (prevention & control), Male, Neuraminidase (immunology), Vaccines, Attenuated (administration & dosage), Vaccines, Attenuated (adverse effects).
- MESH :
- chemical , administration & dosage : Influenza Vaccines, Vaccines, Attenuated.
- chemical , adverse effects : Influenza Vaccines, Vaccines, Attenuated.
- chemical , analysis : Antibodies, Viral.
- immunology : Influenza A virus, Neuraminidase.
- prevention & control : Influenza, Human.
- chemical , therapeutic use : Influenza Vaccines.
- Administration, Intranasal, Adult, Child, Clinical Trials as Topic, Female, Hemagglutination Inhibition Tests, Humans, Male.
Abstract
Live temperature-sensitive influenza virus vaccines were tested in two volunteer experiments. The vaccine virus was originally derived from a temperature-sensitive mutant of influenza A/Great Lakes/1965 (H2N2) produced by chemical mutagenesis with 5-fluorouracil. The ts lesions of this strain were subsequently transferred (HI) antibody. Only 9 men (13%) were infected, presumably as a result of over-attenuation of the virus and/or insufficient titer of the inoculum. In the second experiment (1974), 20 young adults were given 0.5 ml per nostril of vaccine containing a recombinant of influenza A/Udorn/307/72 clone 24 (10(5.5) TCID50/ml) with an in vitro shutoff temperature of 38 degree C. Virus was shed by seven volunteers (maximum titer, 10(2.5)TCID50/ml). None of 21 isolates contained revertant wild type virus. Serum HI and antieuraminidase (NI) and nasal wash neutralizing antibody responses occurred in 11 (55%), 7 (35%), and 8 (40%) volunteers, respectively. Post-vaccination serum HI and NI and nasal neutralizing antibody geometric mean titers were 3.0, 9.4, and 1.7 lob2, respectively. Seven volunteers judged they had colds (symptom scores 4-32). Rhinitis and mild pharyngeal discomfort were the only consistent complaints and fever was absent. The findings in the latter trial will be compared with results of volunteer experiments with Udorn/72 ts-1-(E) in other laboratories and to studies with standard inactivated influenza vaccines given parenterally.
PubMed: 782966
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000647
- to stream PubMed, to step Curation: 000647
- to stream PubMed, to step Checkpoint: 000553
- to stream Ncbi, to step Merge: 001297
- to stream Ncbi, to step Curation: 001297
- to stream Ncbi, to step Checkpoint: 001297
- to stream Main, to step Merge: 002C62
- to stream Main, to step Curation: 002B01
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The use of live attenuated influenza vaccine ts-1(E) in man.</title><author><name sortKey="Gwaltney, J M" sort="Gwaltney, J M" uniqKey="Gwaltney J" first="J M" last="Gwaltney">J M Gwaltney</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1976">1976</date><idno type="RBID">pubmed:782966</idno><idno type="pmid">782966</idno><idno type="wicri:Area/PubMed/Corpus">000647</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000647</idno><idno type="wicri:Area/PubMed/Curation">000647</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000647</idno><idno type="wicri:Area/PubMed/Checkpoint">000553</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000553</idno><idno type="wicri:Area/Ncbi/Merge">001297</idno><idno type="wicri:Area/Ncbi/Curation">001297</idno><idno type="wicri:Area/Ncbi/Checkpoint">001297</idno><idno type="wicri:doubleKey">0301-5149:1976:Gwaltney J:the:use:of</idno><idno type="wicri:Area/Main/Merge">002C62</idno><idno type="wicri:Area/Main/Curation">002B01</idno><idno type="wicri:Area/Main/Exploration">002B01</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The use of live attenuated influenza vaccine ts-1(E) in man.</title><author><name sortKey="Gwaltney, J M" sort="Gwaltney, J M" uniqKey="Gwaltney J" first="J M" last="Gwaltney">J M Gwaltney</name></author></analytic><series><title level="j">Developments in biological standardization</title><idno type="ISSN">0301-5149</idno><imprint><date when="1976" type="published">1976</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Intranasal</term><term>Adult</term><term>Antibodies, Viral (analysis)</term><term>Child</term><term>Clinical Trials as Topic</term><term>Female</term><term>Hemagglutination Inhibition Tests</term><term>Humans</term><term>Influenza A virus (immunology)</term><term>Influenza Vaccines (administration & dosage)</term><term>Influenza Vaccines (adverse effects)</term><term>Influenza Vaccines (therapeutic use)</term><term>Influenza, Human (prevention & control)</term><term>Male</term><term>Neuraminidase (immunology)</term><term>Vaccines, Attenuated (administration & dosage)</term><term>Vaccines, Attenuated (adverse effects)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Administration par voie nasale</term><term>Adulte</term><term>Anticorps antiviraux (analyse)</term><term>Enfant</term><term>Essais cliniques comme sujet</term><term>Femelle</term><term>Grippe humaine ()</term><term>Humains</term><term>Mâle</term><term>Sialidase (immunologie)</term><term>Tests d'inhibition de l'hémagglutination</term><term>Vaccins antigrippaux (administration et posologie)</term><term>Vaccins antigrippaux (effets indésirables)</term><term>Vaccins antigrippaux (usage thérapeutique)</term><term>Vaccins atténués (administration et posologie)</term><term>Vaccins atténués (effets indésirables)</term><term>Virus de la grippe A (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term><term>Vaccines, Attenuated</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Influenza Vaccines</term><term>Vaccines, Attenuated</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antigrippaux</term><term>Vaccins atténués</term></keywords><keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>Anticorps antiviraux</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Vaccins antigrippaux</term><term>Vaccins atténués</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Sialidase</term><term>Virus de la grippe A</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A virus</term><term>Neuraminidase</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Intranasal</term><term>Adult</term><term>Child</term><term>Clinical Trials as Topic</term><term>Female</term><term>Hemagglutination Inhibition Tests</term><term>Humans</term><term>Male</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Administration par voie nasale</term><term>Adulte</term><term>Enfant</term><term>Essais cliniques comme sujet</term><term>Femelle</term><term>Grippe humaine</term><term>Humains</term><term>Mâle</term><term>Tests d'inhibition de l'hémagglutination</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Live temperature-sensitive influenza virus vaccines were tested in two volunteer experiments. The vaccine virus was originally derived from a temperature-sensitive mutant of influenza A/Great Lakes/1965 (H2N2) produced by chemical mutagenesis with 5-fluorouracil. The ts lesions of this strain were subsequently transferred (HI) antibody. Only 9 men (13%) were infected, presumably as a result of over-attenuation of the virus and/or insufficient titer of the inoculum. In the second experiment (1974), 20 young adults were given 0.5 ml per nostril of vaccine containing a recombinant of influenza A/Udorn/307/72 clone 24 (10(5.5) TCID50/ml) with an in vitro shutoff temperature of 38 degree C. Virus was shed by seven volunteers (maximum titer, 10(2.5)TCID50/ml). None of 21 isolates contained revertant wild type virus. Serum HI and antieuraminidase (NI) and nasal wash neutralizing antibody responses occurred in 11 (55%), 7 (35%), and 8 (40%) volunteers, respectively. Post-vaccination serum HI and NI and nasal neutralizing antibody geometric mean titers were 3.0, 9.4, and 1.7 lob2, respectively. Seven volunteers judged they had colds (symptom scores 4-32). Rhinitis and mild pharyngeal discomfort were the only consistent complaints and fever was absent. The findings in the latter trial will be compared with results of volunteer experiments with Udorn/72 ts-1-(E) in other laboratories and to studies with standard inactivated influenza vaccines given parenterally.</div></front></TEI><affiliations><list></list><tree><noCountry><name sortKey="Gwaltney, J M" sort="Gwaltney, J M" uniqKey="Gwaltney J" first="J M" last="Gwaltney">J M Gwaltney</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002B01 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002B01 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:782966
|texte= The use of live attenuated influenza vaccine ts-1(E) in man.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:782966" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a H2N2V1
| This area was generated with Dilib version V0.6.33. |  |